187 related articles for article (PubMed ID: 25081337)
1. Synchronous non-small cell lung cancers: diagnostic yield can be improved by histologic and genetic methods.
Zhang Y; Hu H; Wang R; Ye T; Pan Y; Wang L; Zhang Y; Li H; Li Y; Shen L; Yu Y; Sun Y; Chen H; Garfield D
Ann Surg Oncol; 2014 Dec; 21(13):4369-74. PubMed ID: 25081337
[TBL] [Abstract][Full Text] [Related]
2. Surgical results of synchronous multiple primary lung cancers: similar to the stage-matched solitary primary lung cancers?
Yu YC; Hsu PK; Yeh YC; Huang CS; Hsieh CC; Chou TY; Hsu HS; Wu YC; Huang BS; Hsu WH
Ann Thorac Surg; 2013 Dec; 96(6):1966-74. PubMed ID: 24021769
[TBL] [Abstract][Full Text] [Related]
3. Surgical treatment of primary lung cancer with synchronous brain metastases.
Billing PS; Miller DL; Allen MS; Deschamps C; Trastek VF; Pairolero PC
J Thorac Cardiovasc Surg; 2001 Sep; 122(3):548-53. PubMed ID: 11547308
[TBL] [Abstract][Full Text] [Related]
4. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
[TBL] [Abstract][Full Text] [Related]
5. [Survival after surgical treatment of bilateral synchronous multiple primary non-small cell lung cancers].
Zhang ZR; Mao YS; Gao SG; Mu JW; Xue Q; Wang DL; Gao YS; Zhao J; He J
Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):460-5. PubMed ID: 27346405
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases.
Girard N; Deshpande C; Lau C; Finley D; Rusch V; Pao W; Travis WD
Am J Surg Pathol; 2009 Dec; 33(12):1752-64. PubMed ID: 19773638
[TBL] [Abstract][Full Text] [Related]
7. Simultaneously presenting head and neck and lung cancer: a diagnostic and treatment dilemma.
Kuriakose MA; Loree TR; Rubenfeld A; Anderson TM; Datta RV; Hill H; Rigual NR; Orner J; Singh A; Hicks WL
Laryngoscope; 2002 Jan; 112(1):120-3. PubMed ID: 11802049
[TBL] [Abstract][Full Text] [Related]
8. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
9. Survival after resection of synchronous non-small cell lung cancer.
Fabian T; Bryant AS; Mouhlas AL; Federico JA; Cerfolio RJ
J Thorac Cardiovasc Surg; 2011 Sep; 142(3):547-53. PubMed ID: 21843760
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mutational changes in involved N1 lymph nodes with those in primary tumors in stage II non-small cell lung cancer: a pilot study.
Fernando HC; Sasatomi E; Christie NA; Buenaventura PO; Finkelstein SD; Yousem SA; Soose R; Close JM; Luketich JD
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):87-91. PubMed ID: 14752417
[TBL] [Abstract][Full Text] [Related]
11. High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.
Maeng CH; Lee HY; Kim YW; Choi MK; Hong JY; Jung HA; Lee KS; Kim H; Kwon OJ; Sun JM; Ahn JS; Park K; Um SW; Ahn MJ
Anticancer Res; 2013 Nov; 33(11):5127-33. PubMed ID: 24222160
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
16. The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathologic characteristics.
Sterlacci W; Tzankov A; Veits L; Oberaigner W; Schmid T; Hilbe W; Fiegl M
Am J Clin Pathol; 2011 Apr; 135(4):611-8. PubMed ID: 21411784
[TBL] [Abstract][Full Text] [Related]
17. The Value of Prognostic Factors for Survival in Synchronous Multifocal Lung Cancer: A Retrospective Analysis of 164 Patients.
Lv J; Zhu D; Wang X; Shen Q; Rao Q; Zhou X
Ann Thorac Surg; 2018 Mar; 105(3):930-936. PubMed ID: 29394993
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Koyama N; Uchida Y
Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of TIMP-1 in non-small cell lung cancer.
Pesta M; Kulda V; Kucera R; Pesek M; Vrzalova J; Liska V; Pecen L; Treska V; Safranek J; Prazakova M; Vycital O; Bruha J; Holubec L; Topolcan O
Anticancer Res; 2011 Nov; 31(11):4031-8. PubMed ID: 22110238
[TBL] [Abstract][Full Text] [Related]
20. Genetic variations associated with postoperative recurrence in stage I non-small cell lung cancer.
Yoon KA; Jung MK; Lee D; Bae K; Joo JN; Lee GK; Lee HS; Lee JS
Clin Cancer Res; 2014 Jun; 20(12):3272-9. PubMed ID: 24737549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
